Renal Biomarkers Market, by Biomarker Type (Functional Biomarker (Serum Creatinine, Serum Cystatin C, Urine Albumin), Up-Regulated Proteins (Neutrophil gelatinase-associated lipocalin, Kidney injury molecule 1, Interleukin 18), Others, By Technique (Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay, Liquid Chromatography-Mass Spectrometry), By End User (Diagnostic Labs, Outpatient Clinics, Research Centers, Hospitals), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) -

Published In : Jul 2023

Code : CMI3551

Pages :145

Formats :

Excel and PDF

Industry : Clinical Diagnostic

Market Challenges And Opportunities

Global Renal Biomarkers Market– Driver

Rising incidence of chronic kidney diseases and growing geriatric population

Rising incidence of chronic kidney diseases is expected to boost the growth of the global renal biomarkers market over the forecast period. For instance, according to an article in british medical journal in January 2020, the number of dialysis patients on the kidney transplant waiting list as of December, 2017 marked a third consecutive year of decline with an 8.8% reduction from the previous year, to 75,745 candidates, 85% of whom were awaiting their first kidney transplant. The waiting period increases the prevalence of CKD.

Product Launch from the key players

Over the forecast period, key players' newly released products typically drive the renal biomarkers market. For instance, on May 16, 2023, Aravive, Inc., a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced positive new data from the Phase 1b portion of the ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell cancer (ccRCC) and new data from a biomarker high subgroup.

Limitations Associated With Renal Biomarkers

Because it is impossible to adhere to the same guidelines that would apply to the use of indicators that are not biological, many research using biomarkers are never finished. Any biomarker development should take place prior to or concurrent with the usual design of any clinical trial or epidemiological study. A thorough analysis of the biomarkers' validity in relation to the disease's stage is required. So proper selection of biomarker for diagnosis to be used. For instance, in April 2021, an article published in the Journal of Nephrology, therenal biomarkers have several disadvatages such as Laboratory errors, inaccuracy, Normal range difficult to establish and Ethical responsibility.

Low sensitivity and specificity

Low sensitivity and specificity of biomarkers is expected to hinder the growth of the global renal biomarkers market over the forecast period. For instance, in November 2021, according to an article published in the Journal of Contemporary Practice in Clinical Chemistry, an article states that the creatinine assay is subjected to interference because of intake of certain drugs or because of certain pathophysiological states including hyperbilirubinemia and diabetic ketoacidosis. Serum Creatinine is nonspecific in conditions such as prerenal azotemia where creatinine levels can rise without tubular injury. Because of all these undesirable limitations of creatinine as a marker, there has been a great deal of interest in the identification of improved biomarkers for kidney injury.

Restraints